Agreements with Innovators

To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.

Negotiating public health-driven licences with patent holders, sublicensing to generic manufacturers and product developers, and supporting access to those treatments in LMICs, are the core work of the Medicines Patent Pool.

Below is an overview of all our licensing and sublicensing agreements, and other agreements on specific products with partners. For more information, click on the product, patent holder, generic partner or product developer you are interested in.


Patent Holder

Generic Manufacturers and Other Licensees



MPP Logo

Subscribe to our Newsletter

Founded & funded by

Unitaid Logo

Other funders